221 related articles for article (PubMed ID: 30784672)
21. Anthracycline Cardiotoxicity: How Do We Move From Diagnosis to Prediction?
Lustberg MB; Zareba KM
Circ Cardiovasc Imaging; 2016 Aug; 9(8):. PubMed ID: 27502063
[No Abstract] [Full Text] [Related]
22. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
Bryant J; Picot J; Levitt G; Sullivan I; Baxter L; Clegg A
Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809
[TBL] [Abstract][Full Text] [Related]
23. Subendocardial late gadolinium enhancement in two patients with anthracycline cardiotoxicity following treatment for Ewing's sarcoma.
Perel RD; Slaughter RE; Strugnell WE
J Cardiovasc Magn Reson; 2006; 8(6):789-91. PubMed ID: 17060100
[TBL] [Abstract][Full Text] [Related]
24. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
Sieswerda E; van Dalen EC; Postma A; Cheuk DK; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2011 Sep; (9):CD008011. PubMed ID: 21901716
[TBL] [Abstract][Full Text] [Related]
25. CMR and Tissue Characterization: Don't Forget the Strain!
Connelly KA; Yan AT; Amir E; Thavendiranathan P
J Am Coll Cardiol; 2019 Jul; 73(25):3359. PubMed ID: 31248561
[No Abstract] [Full Text] [Related]
26. Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
van Dalen EC; Michiels EM; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2006 Oct; (4):CD005006. PubMed ID: 17054231
[TBL] [Abstract][Full Text] [Related]
27. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities.
Vejpongsa P; Yeh ET
J Am Coll Cardiol; 2014 Sep; 64(9):938-45. PubMed ID: 25169180
[TBL] [Abstract][Full Text] [Related]
28. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.
Cardinale D; Colombo A; Bacchiani G; Tedeschi I; Meroni CA; Veglia F; Civelli M; Lamantia G; Colombo N; Curigliano G; Fiorentini C; Cipolla CM
Circulation; 2015 Jun; 131(22):1981-8. PubMed ID: 25948538
[TBL] [Abstract][Full Text] [Related]
29. Myocardial Characterization Using Dual-Energy CT in Doxorubicin-Induced DCM: Comparison With CMR T1-Mapping and Histology in a Rabbit Model.
Hong YJ; Kim TK; Hong D; Park CH; Yoo SJ; Wickum ME; Hur J; Lee HJ; Kim YJ; Suh YJ; Greiser A; Paek MY; Choi BW
JACC Cardiovasc Imaging; 2016 Jul; 9(7):836-845. PubMed ID: 27236517
[TBL] [Abstract][Full Text] [Related]
30. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children.
Ekstein S; Nir A; Rein AJ; Perles Z; Bar-Oz B; Salpeter L; Algur N; Weintraub M
J Pediatr Hematol Oncol; 2007 Jul; 29(7):440-4. PubMed ID: 17609620
[TBL] [Abstract][Full Text] [Related]
31. Anthracycline-induced cardiotoxicity: comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials.
van Dalen EC; van den Brug M; Caron HN; Kremer LC
Eur J Cancer; 2006 Dec; 42(18):3199-205. PubMed ID: 17011186
[TBL] [Abstract][Full Text] [Related]
32. Pediatric quality of life in long-term survivors of childhood cancer treated with anthracyclines.
Ryerson AB; Wasilewski-Masker K; Border WL; Goodman M; Meacham L; Austin H; Marchak JG; Mertens AC
Pediatr Blood Cancer; 2016 Dec; 63(12):2205-2211. PubMed ID: 27442487
[TBL] [Abstract][Full Text] [Related]
33. Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity.
Lotrionte M; Biondi-Zoccai G; Abbate A; Lanzetta G; D'Ascenzo F; Malavasi V; Peruzzi M; Frati G; Palazzoni G
Am J Cardiol; 2013 Dec; 112(12):1980-4. PubMed ID: 24075281
[TBL] [Abstract][Full Text] [Related]
34. Response by Bernstein to Letter Regarding Article, "Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking?".
Bernstein D
Circ Res; 2018 Mar; 122(7):e64-e65. PubMed ID: 29599280
[No Abstract] [Full Text] [Related]
35. [Cardiotoxicity of anthracyclines].
Costache II; Petriş A
Rev Med Chir Soc Med Nat Iasi; 2011; 115(4):1200-7. PubMed ID: 22276470
[TBL] [Abstract][Full Text] [Related]
36. Pharmacogenomic screening for anthracycline-induced cardiotoxicity in childhood cancer.
Aminkeng F; Ross CJD; Rassekh SR; Rieder MJ; Bhavsar AP; Sanatani S; Bernstein D; Hayden MR; Amstutz U; Carleton BC
Br J Clin Pharmacol; 2017 May; 83(5):1143-1145. PubMed ID: 28317142
[No Abstract] [Full Text] [Related]
37. Occult cardiotoxicity in childhood cancer survivors exposed to anthracycline therapy.
Toro-Salazar OH; Gillan E; O'Loughlin MT; Burke GS; Ferranti J; Stainsby J; Liang B; Mazur W; Raman SV; Hor KN
Circ Cardiovasc Imaging; 2013 Nov; 6(6):873-80. PubMed ID: 24097420
[TBL] [Abstract][Full Text] [Related]
38. T2 Mapping Identifies Early Anthracycline-Induced Cardiotoxicity in Elderly Patients With Cancer.
Martin-Garcia A; Diaz-Pelaez E; Lopez-Corral L; Sanchez-Pablo C; Macias de Plasencia G; Galan-Arriola C; Sanchez-Gonzalez J; Cruz JJ; Ibanez B; Sanchez PL
JACC Cardiovasc Imaging; 2020 Jul; 13(7):1630-1632. PubMed ID: 32199840
[No Abstract] [Full Text] [Related]
39. Oxidative Stress and Cellular Response to Doxorubicin: A Common Factor in the Complex Milieu of Anthracycline Cardiotoxicity.
Cappetta D; De Angelis A; Sapio L; Prezioso L; Illiano M; Quaini F; Rossi F; Berrino L; Naviglio S; Urbanek K
Oxid Med Cell Longev; 2017; 2017():1521020. PubMed ID: 29181122
[TBL] [Abstract][Full Text] [Related]
40. Anthracycline-Induced Cardiotoxicity: Time to Focus on Cardioprotection Again.
Croft AJ; Ngo DTM; Sverdlov AL
Heart Lung Circ; 2019 Oct; 28(10):1454-1456. PubMed ID: 31495502
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
